GS 4774

Drug Profile

GS 4774

Alternative Names: GI 13020; GS-4774; Inactivated recombinant Saccharomyces cerevisiae expressing Hepatitis B virus X, surface and core antigens (GI-13020); Tarmogen T cell immunity stimulator

Latest Information Update: 29 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlobeImmune
  • Developer Gilead Sciences
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 15 Jun 2018 GS 4774 is still in phase II trials for Hepatitis B (GlobeImmune pipeline, June 2018)
  • 30 May 2018 Gilead Sciences completes a phase II trial in Hepatitis B (Combination therapy) in USA, Canada, New Zealand, Romania, South Korea and Italy (SC) (NCT02174276)
  • 19 Apr 2017 Updated efficacy and immunological data from a phase II trial in Hepatitis B presented at the International Liver Congress (ILC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top